{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-Infectious+Disorder+%28Disorder%29&page=12", "query": { "condition": "Post-Infectious Disorder (Disorder)", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 657, "total_pages": 66, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-Infectious+Disorder+%28Disorder%29&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Post-Infectious+Disorder+%28Disorder%29&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:23:28.110Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06511063", "title": "Antiviral Clinical Trial for Long Covid-19", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long Covid" ], "interventions": [ { "name": "tenofovir disoproxil/emtricitabine", "type": "DRUG" }, { "name": "Selzentry", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2024-10-01", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06511063" }, { "nct_id": "NCT02412917", "title": "A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Shingles", "Herpes Zoster", "Postherpetic Neuralgia" ], "interventions": [ { "name": "FV-100", "type": "DRUG" }, { "name": "valacyclovir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ContraVir Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 237, "start_date": "2015-06", "completion_date": "2017-11", "has_results": false, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "Webster, Texas", "locations": [ { "city": "Webster", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02412917" }, { "nct_id": "NCT06171152", "title": "Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Multiple Sclerosis", "Long COVID", "Long Covid19", "Obese", "Obesity", "Obesity, Morbid", "Acute Leukemia in Remission" ], "interventions": [ { "name": "Liraglutide Pen Injector [Saxenda]", "type": "DRUG" }, { "name": "Medication Diary", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 30, "start_date": "2024-01-26", "completion_date": "2027-10-01", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06171152" }, { "nct_id": "NCT00711035", "title": "Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenovirus Infection", "EBV Infection" ], "interventions": [ { "name": "Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 50, "start_date": "2008-11", "completion_date": "2013-08", "has_results": false, "last_update_posted_date": "2016-04-26", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 8, "location_summary": "Los Angeles, California • Coral Gables, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Bergen County", "state": "New Jersey" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711035" }, { "nct_id": "NCT00324324", "title": "Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Gestational Trophoblastic Tumor", "Infection", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Neuroblastoma", "Ovarian Cancer", "Testicular Germ Cell Tumor" ], "interventions": [ { "name": "moxifloxacin hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 240, "start_date": "2006-05", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00324324" }, { "nct_id": "NCT00872196", "title": "A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Virus Infection" ], "interventions": [ { "name": "ABT-072", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 5, "start_date": "2009-04", "completion_date": "2010-04", "has_results": false, "last_update_posted_date": "2013-04-01", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00872196" }, { "nct_id": "NCT06404099", "title": "RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Long COVID-19", "Hypersomnia" ], "interventions": [ { "name": "Modafinil", "type": "DRUG" }, { "name": "Modafinil Placebo", "type": "DRUG" }, { "name": "Solriamfetol", "type": "DRUG" }, { "name": "Solriamfetol Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 361, "start_date": "2024-08-12", "completion_date": "2026-04-20", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06404099" }, { "nct_id": "NCT01582763", "title": "International Guillain-Barré Syndrome Outcome Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Guillain-Barré Syndrome", "Miller Fisher Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Erasmus Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 2000, "start_date": "2012-05-01", "completion_date": "2024-12-02", "has_results": false, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Orange, California • New Haven, Connecticut + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01582763" }, { "nct_id": "NCT05877508", "title": "Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long COVID", "Post-Acute Sequela of COVID-19", "Post-Acute COVID-19" ], "interventions": [ { "name": "AER002", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Michael Peluso, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-08-01", "completion_date": "2026-07-31", "has_results": true, "last_update_posted_date": "2025-10-28", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05877508" }, { "nct_id": "NCT01603108", "title": "Rifaximin to Prevent Recurrent HCV-Related Fibrosis After Liver Transplant", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Rifaximin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 59, "start_date": "2012-03", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2016-04-22", "last_synced_at": "2026-10-24T00:23:28.110Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01603108" } ] }